Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between age and mortality in men with adult-onset testosterone deficiency is altered by testosterone therapy.

The aging male : the official journal of the International Society for the Study of the Aging Male·2026
Same author

Can Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non-Obstructive Azoospermia?

Andrology·2026
Same author

[Male contraception-scientific foundations and contemporary progress].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2026
Same author

Vitamin D levels in relation to sexual steroids, sexual function, and quality of life in patients of an andrology outpatient clinic.

The aging male : the official journal of the International Society for the Study of the Aging Male·2026
Same author

Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies.

Maturitas·2026
Same author

The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems.

The aging male : the official journal of the International Society for the Study of the Aging Male·2025

Related Experiment Video

Updated: Jun 21, 2026

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

Pharmacogenetics of testosterone replacement therapy.

Michael Zitzmann1

  • 1Centre for Reproductive Medicine and Andrology, University Clinics Muenster, Domagkstr. 11, D-48149 Muenster, Germany. Michael.Zitzmann@ukmuenster.de

Pharmacogenomics
|August 12, 2009
PubMed
Summary

The length of the CAG repeat polymorphism in the androgen receptor gene influences androgen effects. Longer CAG repeats correlate with reduced androgenic impact, affecting traits and testosterone treatment responses.

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Jun 21, 2026

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

  • Genetics
  • Endocrinology
  • Molecular Biology

Background:

  • Androgen insensitivity in humans often results from androgen receptor defects.
  • Subtle variations in androgen effects are linked to the CAG repeat polymorphism in the androgen receptor gene.

Purpose of the Study:

  • To investigate the clinical significance of the CAG repeat polymorphism in the androgen receptor gene.
  • To explore the relationship between CAG repeat length and androgenicity in eugonadal men.
  • To understand the pharmacogenetic implications of CAG repeat length on testosterone therapy.

Main Methods:

  • Analysis of CAG repeat polymorphism ([CAG]n) in exon 1 of the androgen receptor gene.
  • In vitro studies assessing transcription of androgen-dependent genes.
  • Clinical correlation of CAG repeat length with androgenic traits and testosterone levels.

Main Results:

  • Increased CAG repeat length in the androgen receptor gene attenuates transcription of androgen-dependent genes.
  • Longer (CAG)n correlates with less prominent androgen effects in men with similar testosterone concentrations.
  • CAG repeat length influences the response to externally applied testosterone.

Conclusions:

  • The CAG repeat polymorphism contributes to variable androgenicity and may replace strict hypogonadism thresholds with a genetic continuum.
  • Pharmacogenetic implications of (CAG)n are crucial for guiding testosterone treatment strategies in hypogonadal men.